FMCT Funds Research into Hexokinase 2 Inhibitors at Johns Hopkins

The Foundation for Metabolic Cancer Therapies has awarded a research grant to Dr. Peter Pedersen at John Hopkins School of Medicine. The research will focus on screening for Hexokinase 2 inhibitors. Hexokinase 2 represents one of the most promising metabolic targets within the cancer cell. Dr. Pedersen is an outstanding biochemical researcher with an extraordinary track record, and we are proud to support his research.

Leave a Reply

Your email address will not be published. Required fields are marked *